Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma

Gautam Jha, Jeffrey S. Miller, Julie M. Curtsinger, Yan Zhang, Mathew F. Mescher, Arkadiusz Z. Dudek

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Objective: To evaluate the activity of interleukin-2 (IL-2) in combination with allogeneic large multivalent immunogen (LMI) vaccine, prepared by immobilizing SK23-CD80 + melanoma cell line plasma membrane on 5-mm-diameter silica beads, in patients with melanoma. Methods: Twenty-one patients with metastatic melanoma were randomly assigned to an IL-2 alone control group or an IL-2 plus LMI vaccine treatment group. The primary objective was to evaluate the progression-free survival (PFS) of each group. Secondary clinical objectives included median overall survival (OS) and 1- And 2-year rates of OS. Results: Treatment was very well tolerated. Median PFS was no different between the treatment arm (2.20 mo) and control arm (1.95 mo). Median OS was also similar for the treatment arm (11.89 mo) and control arm (9.97 mo). Conclusions: This study failed to demonstrate that allogeneic LMI vaccine and low-dose IL-2 improved survival in patients with melanoma as compared with low-dose IL-2 alone.

Original languageEnglish (US)
Pages (from-to)261-265
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume37
Issue number3
DOIs
StatePublished - 2014

Keywords

  • Autologous vaccine
  • Large multivalent immunogen vaccine
  • Metastatic malignant melanoma

Fingerprint Dive into the research topics of 'Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma'. Together they form a unique fingerprint.

  • Cite this